PE20051047A1 - COMPUESTOS [1,2,4] TRIAZOL [4,3-b]PIRIDAZIN-3-ONA COMO MODULADORES DE RECEPTOR CANABINOIDE - Google Patents
COMPUESTOS [1,2,4] TRIAZOL [4,3-b]PIRIDAZIN-3-ONA COMO MODULADORES DE RECEPTOR CANABINOIDEInfo
- Publication number
- PE20051047A1 PE20051047A1 PE2005000013A PE2005000013A PE20051047A1 PE 20051047 A1 PE20051047 A1 PE 20051047A1 PE 2005000013 A PE2005000013 A PE 2005000013A PE 2005000013 A PE2005000013 A PE 2005000013A PE 20051047 A1 PE20051047 A1 PE 20051047A1
- Authority
- PE
- Peru
- Prior art keywords
- triazol
- alkyl
- compounds
- pyridazin
- heterocyclyl
- Prior art date
Links
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- HWGUIDNOUFWKEA-UHFFFAOYSA-N 5-(4-chlorophenyl)-1h-1,2,4-triazole Chemical compound C1=CC(Cl)=CC=C1C1=NC=NN1 HWGUIDNOUFWKEA-UHFFFAOYSA-N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 abstract 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- PZKXWVJNJFWQDR-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-methyl-1,2,4-triazole Chemical compound Cn1ncnc1-c1ccc(Cl)cc1 PZKXWVJNJFWQDR-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53145103P | 2003-12-19 | 2003-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20051047A1 true PE20051047A1 (es) | 2005-12-16 |
Family
ID=34710226
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000013A PE20051047A1 (es) | 2003-12-19 | 2005-01-03 | COMPUESTOS [1,2,4] TRIAZOL [4,3-b]PIRIDAZIN-3-ONA COMO MODULADORES DE RECEPTOR CANABINOIDE |
| PE2005000014A PE20050756A1 (es) | 2003-12-19 | 2005-01-03 | Heterociclicos azabiciclicos como moduladores del receptor cannabinoide |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000014A PE20050756A1 (es) | 2003-12-19 | 2005-01-03 | Heterociclicos azabiciclicos como moduladores del receptor cannabinoide |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7037910B2 (enExample) |
| EP (1) | EP1699796A4 (enExample) |
| JP (1) | JP2007514756A (enExample) |
| CN (2) | CN1918165A (enExample) |
| AR (2) | AR047063A1 (enExample) |
| IS (1) | IS8501A (enExample) |
| NO (1) | NO20062689L (enExample) |
| PE (2) | PE20051047A1 (enExample) |
| TW (2) | TW200528455A (enExample) |
| WO (1) | WO2005061509A1 (enExample) |
| ZA (2) | ZA200604645B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100210590A1 (en) * | 1995-09-27 | 2010-08-19 | Northwestern University | Compositions and treatments for seizure-related disorders |
| EP1430033A4 (en) | 2001-08-31 | 2004-12-15 | Univ Northwestern | ANTI-INFLAMMATORY AND PROTEIN-INK-INHIBITING COMPOSITION AND THEIR USE |
| DK1697371T3 (da) | 2003-12-19 | 2007-09-17 | Bristol Myers Squibb Co | Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer |
| US20060025448A1 (en) * | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
| CA2589102C (en) * | 2004-11-02 | 2013-08-13 | Northwestern University | Pyridazine compounds and methods for using the compounds to treat inflammatory diseases |
| ES2441718T3 (es) | 2004-11-02 | 2014-02-06 | Northwestern University | Compuestos de piridazina, composiciones y métodos |
| US7317012B2 (en) * | 2005-06-17 | 2008-01-08 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoind-1 receptor modulators |
| US8722691B2 (en) * | 2006-03-30 | 2014-05-13 | Irm Llc | Azolopyrimidines as inhibitors of cannabinoid 1 activity |
| EP2063894B1 (en) | 2006-04-28 | 2019-08-28 | Northwestern University | Formulations containing pyridazine compounds for treating neuroinflammatory diseases |
| EP2015750A2 (en) * | 2006-04-28 | 2009-01-21 | Northwestern University | Compositions and treatments using pyridazine compounds and cholinesterase inhibitors |
| PL2023909T3 (pl) * | 2006-05-04 | 2010-04-30 | Solvay Pharm Bv | Agonisty muskarynowe do leczenia zaburzeń kontroli impulsów |
| BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
| US20160331729A9 (en) * | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| MX2009010854A (es) * | 2007-04-11 | 2010-01-28 | Omeros Corp | Composiciones y metodos para profilaxis y tratamiento de adicciones. |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2283159B1 (en) * | 2008-05-05 | 2013-10-09 | The Scripps Research Institute | Synthesis of (+) cortistatin a and related compounds |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| ES2443016T3 (es) | 2009-08-26 | 2014-02-17 | Sanofi | Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo |
| FR2958850B1 (fr) * | 2010-04-14 | 2012-07-06 | Centre Nat Rech Scient | Medicaments pour la prevention ou le traitement des addictions aux drogues |
| BR112012027062B8 (pt) * | 2010-04-20 | 2021-05-25 | Fond Ieo | composto, processo para a preparação de um composto e usos do mesmo |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
| WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683703B1 (de) | 2011-03-08 | 2015-05-27 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| JP5437525B1 (ja) | 2012-12-28 | 2014-03-12 | 株式会社ナード研究所 | チロシン誘導体およびチロシン誘導体の製造方法 |
| CN103933569B (zh) * | 2013-01-22 | 2017-01-11 | 复旦大学 | 一种抗肺癌药物组合物及其应用、药盒和包装件 |
| TR201809440T4 (tr) * | 2014-01-29 | 2018-07-23 | Ucb Biopharma Sprl | Protein agregasyonunun inhibitörleri olarak heteroaril amidler. |
| ES2847126T3 (es) * | 2016-06-03 | 2021-07-30 | Univ Columbia | Inhibidores de PDE4 para el tratamiento del síndrome de Prader-Willi |
| CN108178759B (zh) * | 2018-01-05 | 2020-06-09 | 上海瑞纷医药科技有限责任公司 | 一种α-肾上腺素受体拮抗剂的合成方法 |
| CN108498511A (zh) * | 2018-04-21 | 2018-09-07 | 徐晶 | 一种治疗膝关节骨性关节炎的药物组合物及其制备方法 |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1164198B (it) * | 1983-04-28 | 1987-04-08 | Isf Spa | Preparazione di un derivato piridazinico farmacologicamente attivo |
| AU6003099A (en) * | 1998-10-06 | 2000-04-26 | Takeda Chemical Industries Ltd. | Fused pyridazine compounds, process for the preparation of the same and uses thereof |
| JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
| GB0107751D0 (en) * | 2001-03-28 | 2001-05-16 | Pfizer Ltd | Pharmaceutically active compounds |
| JP2005519927A (ja) * | 2002-02-07 | 2005-07-07 | ファイザー・インク | 多嚢胞性卵巣症候群の処置における、シルデナフィル如きｐｄｅ５インヒビターの使用 |
| EP1490335B1 (en) * | 2002-03-25 | 2007-09-19 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| JP2006517958A (ja) | 2003-02-19 | 2006-08-03 | ニューロジェン・コーポレイション | アリール酸ピリミジニルメチルアミド、ピリダジニルメチルアミドおよび関連化合物 |
-
2004
- 2004-12-15 TW TW093138982A patent/TW200528455A/zh unknown
- 2004-12-15 TW TW093138971A patent/TW200530246A/zh unknown
- 2004-12-17 US US11/015,876 patent/US7037910B2/en not_active Expired - Lifetime
- 2004-12-17 AR ARP040104772A patent/AR047063A1/es not_active Application Discontinuation
- 2004-12-17 AR ARP040104771A patent/AR046964A1/es not_active Application Discontinuation
- 2004-12-17 CN CNA2004800419202A patent/CN1918165A/zh active Pending
- 2004-12-17 CN CNA2004800419043A patent/CN1918164A/zh active Pending
- 2004-12-20 WO PCT/US2004/042542 patent/WO2005061509A1/en not_active Ceased
- 2004-12-20 JP JP2006545502A patent/JP2007514756A/ja active Pending
- 2004-12-20 EP EP04814691A patent/EP1699796A4/en not_active Withdrawn
-
2005
- 2005-01-03 PE PE2005000013A patent/PE20051047A1/es not_active Application Discontinuation
- 2005-01-03 PE PE2005000014A patent/PE20050756A1/es not_active Application Discontinuation
-
2006
- 2006-06-06 ZA ZA200604645A patent/ZA200604645B/xx unknown
- 2006-06-08 IS IS8501A patent/IS8501A/xx unknown
- 2006-06-09 ZA ZA200604778A patent/ZA200604778B/xx unknown
- 2006-06-12 NO NO20062689A patent/NO20062689L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200528455A (en) | 2005-09-01 |
| EP1699796A4 (en) | 2009-03-04 |
| ZA200604778B (en) | 2007-12-27 |
| AR046964A1 (es) | 2006-01-04 |
| TW200530246A (en) | 2005-09-16 |
| AR047063A1 (es) | 2006-01-04 |
| WO2005061509A1 (en) | 2005-07-07 |
| PE20050756A1 (es) | 2005-10-06 |
| EP1699796A1 (en) | 2006-09-13 |
| CN1918164A (zh) | 2007-02-21 |
| JP2007514756A (ja) | 2007-06-07 |
| NO20062689L (no) | 2006-09-12 |
| CN1918165A (zh) | 2007-02-21 |
| IS8501A (is) | 2006-06-08 |
| US20050192278A1 (en) | 2005-09-01 |
| US7037910B2 (en) | 2006-05-02 |
| ZA200604645B (en) | 2007-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20051047A1 (es) | COMPUESTOS [1,2,4] TRIAZOL [4,3-b]PIRIDAZIN-3-ONA COMO MODULADORES DE RECEPTOR CANABINOIDE | |
| PE20070021A1 (es) | Compuestos triazolopiridinas como antagonistas de receptor canabinoide 1 | |
| PE20060599A1 (es) | DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1 | |
| PE20060315A1 (es) | Compuestos de tiazol como moduladores de ppar | |
| PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
| PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
| PE20060555A1 (es) | Derivados de pirrol-oxindol como moduladores del receptor de progesterona | |
| PE20091173A1 (es) | Derivados de heteroarilo como antagonistas de receptor de orexina | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20120031A1 (es) | Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1 | |
| AR049696A1 (es) | Derivados de indol | |
| PE20060459A1 (es) | DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA COMO INHIBIDORES DE LA ß-SECRETASA | |
| PE20160691A1 (es) | Nuevos derivados de triazolo[4,5-d]pirimidina | |
| PE20040600A1 (es) | Derivados de triazol como antagonistas del receptor de taquicinina | |
| PE20051173A1 (es) | Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3 | |
| PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
| PE20110875A1 (es) | Derivados de isoindol como inhibidores de bace | |
| PE20080139A1 (es) | Compuestos de pirrolotriazina anilina como inhibidores de cinasa | |
| JP2009532504A5 (enExample) | ||
| PE20051054A1 (es) | Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento | |
| PE20081665A1 (es) | Antagonistas del receptor de dopamina 2 de rapida disociacion | |
| PE20080136A1 (es) | Arilsulfonamidas sustituidas como agentes antivirales | |
| JPWO2005077912A1 (ja) | インダゾール化合物及びその医薬用途 | |
| PE20061038A1 (es) | Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion | |
| PE20050141A1 (es) | DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |